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Abstract
Aim: The aim of this study was to evaluate the suitability of Sensititre YeastOne (SYO) method for
susceptibility profiles’ determination of non-Aspergillus moulds and of E-test for Aspergillus spp. and
non-Aspergillus moulds, in comparison with the M38-A reference broth microdilution (BMD) method.
Material and Methods: A total of 33 clinical isolates of filamentous fungi were tested.
Results: The agreement between E-test and BMD at ± 2 dilutions was 82.4%, 83.3% and 82.4% for
amphotericin B, itraconazole and voriconazole, respectively. The agreement between SYO and BMD
at ± 2 dilutions was 76.5%, 66.7% and 88.2% for amphotericin B, itraconazole and voriconazole,
respectively. The majority of differing results are due to higher MICs with the reference method. In
particular, SYO was unable to detect some of the potentially amphotericin B resistant strains. We found
that both E-test and SYO method were reproducible and served as suitable methods for antifungal
susceptibility testing of moulds.
Conclusion: In conclusion, both E-test and SYO method are promising, but require further investigation
to identify the optimum conditions for their use in testing of susceptibility profiles of filamentous fungi to
antifungal agents.
Introduction
The impact and severity of fungal infections
have grown in recent decades and now involve a wide
range of fungal pathogens as etiological agents. During
this period, the number of immunocompromised patients
has markedly increased [1]. Many predisposing factors
have contributed to this increase such as use of new and
more aggressive therapies for treatment of solid tumours,
haematological malignancies, long-term therapy with
corticosteroids and broad-spectrum antibiotics, the
increasing number of patients who undergo organ
transplantation, and finally the spread of AIDS [2]. The
management of fungal infections is affected by the ability
to carry out rapid and effective etiological diagnosis and
availability of antifungal agents with proper spectrum of
activity [3]. Delayed diagnosis and antifungal treatment
contribute significantly to the high mortality rates
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associated with invasive fungal infections [4], whereas
early intervention with antifungal drugs may result in
more effective management of high-risk patients [5].
Knowledge of potential causative organisms is
required to aid the diagnostic process, mainly in situations
where systemic fungal infection is suspected but the
clinical presentation is nonspecific [6]. The exact
identification of the etiological agent has become essential
in light of the increased use of prophylactic regimens that
predispose the patients’ development of fungal infection
and selection of resistant fungal species, such as Candida
glabrata, C. krusei, Aspergillus terreus, Scedosporium
species and Zygomycetes, many of which are intrinsically
resistant to the available antifungal agents [7].
It is therefore very important to perform in vitro
antifungal susceptibility testing (AFST) which should
provide useful information for appropriate selection of
the most active antifungal therapy against different
etiological agents, as well as to predict treatment outcome
or explain some resistance cases [8]. In 2002, the CLSI
(Clinical and Laboratory Standards Institute, formerly
NCCLS) published approved guidelines (M38-A) for
broth microdilution susceptibility testing of Aspergillus
spp. and other rapidly growing filamentous moulds (BMD)
[9]. With the establishment of this reference method,
there is now an opportunity to validate alternative methods
for testing moulds against various systemically active
antifungal agents. However this method is not a practical
testing tool for a busy microbiology laboratory, because
it is time-consuming and cumbersome [10].
Therefore, there is a great need for an easier
and reproducible method for in vitro AFST of filamentous
fungi. Alternatives to the CLSI method are E-test and
Sensititre YeastOne (SYO) antifungal panel, two
commercial methods that have been evaluated for yeasts
and moulds [11-16]. SYO is a commercial colorimetric
panel, that consists of a disposable tray which contains
dried serial dilutions of seven antifungal agents in
individual wells, which also contain an oxidation-reduction
indicator (AlamarBlue) to generate clear-cut endpoints
based on a visually detectable change in colour from
blue to pink, and this indicates the antifungal activity,
reducing the problems caused by the trailing effect in the
visual endpoints [11, 14, 16]. The agar-based E-test
method (AB Biomerieux, France) is a commercially
available, pre-formed, pre-defined and stable antibiotic
method, which uses a plastic test strip impregnated with
a continuous concentration gradient of an antifungal
agent to determine the minimum inhibitory concentration
(MIC) necessary for inhibition of fungal growth [15-17].
It has been proven as a useful method in testing Candida
spp. against a variety of antifungal agents, including
amphotericin B, the azoles and caspofungin [8, 18-20].
The aim of this study was to evaluate the
suitability of SYO method for susceptibility profiles’
determination of non-Aspergillus moulds and of E-test
for Aspergillus spp. and non-Aspergillus moulds, and,
where available, other methods. The study was performed
at the Laboratory for Medical Mycology at the Institute for
Medical Microbiology, University of Zürich, Switzerland.
Material and Methods
Test isolates
In this study, a total of 33 clinical isolates
belonging to different species of filamentous fungi from
the collection of the mycology laboratory (Aspergillus
fumigatus (9), A. glaucus (2), A. flavus (1), A. niger (1),
A. nidulans (1), A. sclerotiorum (1) A. versicolor (1),
Fusarium spp. (5), Paecilomyces variotii (1),
Paecilomyces spp. (3), Scedosporium apiospermum
(5), Scedosporium prolificans (2), Scopulariopsis spp.
(1)), were tested during a fellowship stay at the Laboratory
for Medical Mycology at the Institute for Medical
Microbiology, University of Zürich, Switzerland in 2006.
Minimum inhibitory concentrations have been
determined with Sensititre YeastOne (SYO) method (for
Aspergillus spp.) and BMD method (for non-Aspergillus
moulds). Culture and identification of the strains were
done by using conventional mycological methods. All
isolates were stored in skim milk at –70oC until they were
used in the study. They were restored and subsequently
passed at least twice on potato carrot agar (non-
Aspergillus moulds) and malt yeast agar (Aspergillus
spp.) to ensure viability and adequate sporulation before
AFST with E-test (Aspergillus spp. and non-Aspergillus
moulds) and SYO (non-Aspergillus moulds) was
performed. Inoculum suspensions were prepared from
5-7 days cultures in sterile saline solution with Tween 80
for SYO method as well as for E-test. These suspensions
were vortexed for 15 seconds to allow complete uniformity
and left for another 15 minutes to allow sedimentation of
hyphae. Final inocula were achieved by counting the
number of conidia in a Neubauer chamber and were in
the range between 0.5x106-5x106CFU/ml for SYO
method and E-test. A confirmatory plate count was done
from a 1:1000 dilution to ensure inoculum density on
brain heart infusion agar (expected colony forming units
(CFU)=15-80; all inocula were in the range between 15-
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80 CFU). The quality control (QC) strain C. parapsilosis
ATCC 22019 (9) was included as control strain for both
methods.
M38-A reference broth microdilution
method (BMD)
A broth microdilution was performed according
to the CLSI document M38-A using colorimetric
endpoints. The antifungal drugs used in the study were
obtained as reagent-grade powders: amphotericin B
(AB) (Sigma Chemical Co.), itraconazole (IZ) (Janseen
B, itraconazole), from 0.03 to 8 μg/ml (voriconazole),
and from 0.06 to 16 μg/ml (caspofungin). The inoculated
microdilution trays containing Alamar blue were incubated
at 35oC and read at 24, 48 and 72 hours. Growth of
filamentous fungi was evident as a change in the
colorimetric growth indicator from blue (negative) to red
(positive). The MIC endpoint was defined as the lowest
concentration that produced complete inhibition of growth,
i.e., the first blue well (for amphotericin B) or the lowest
concentration that substantially inhibited growth, i.e., the
first well which changed colour from blue to pink or red
(for azoles and caspofungin) [9].
Figure 1: Microdilution trays for the reference broth microdilution
method.
Figure 2: SYO5 Sensititre panels.
Sensititre Yeast One method (SYO
method)
SYO5 panels (Trek Diagnostic System, UK)
with incorporated Alamar blue containing twofold serial
dilutions of dried antifungal drugs were used (Fig. 2).
The concentration range for each agent is as follows
(Amphotericin B = 0.008-16 μg/ml; Fluconazole = 0.125-
256 μg/ml; Itraconazole = 0.008-16 μg/ml; Ketoconazole
= 0.008-16 μg/ml; Flucytosine = 0.03-64 μg/ml;
Figure 3: E-test gradient strips of different antifungal agents.
Pharmaceutica), voriconazole (VZ) (Pfizer). Stock
solutions of the antifungal agents were prepared in
100% dimethyl sulfoxide and diluted 100 times to their
final concentration, further diluted in RPMI 1640 medium,
for all antifungal agents (except for amphotericin B, for
which AM3 was used), buffered to pH 7.0 with MOPS
buffer, and dispensed into 96-well microdilution trays
(Fig. 1). The final concentration of the antifungal agents
in the wells ranged from 0.06 to 16 μg/ml (amphotericin
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Voriconazole = 0.008-16 μg/ml; Caspofungin = 0.008-
16 μg/ml). Inoculum suspensions were diluted 1:100 in
YeastOne RPMI medium, the dried SYO panels were
rehydrated with 100 ml of the working suspension which
was dispensed into each well with a multichannel
pippeting device. The panels were covered with seal
strips and incubated at 35oC for 24, 48 and 72 hours in
a non-CO2 incubator and then visually read under normal
laboratory lighting. Growth of filamentous fungi was
evident as a change in the colorimetric growth indicator
from blue (negative) to red (positive). The colorimetric
MIC was considered to be the lowest concentration of an
antifungal agent without any change in the colour (i.e.,
the first blue well) [11].
E-test method
The E-test method was performed in accordance
with the manufacturer’s instructions. E-test gradient
strips of amphotericin B (AB), itraconazole (IZ),
voriconazole (VZ), and caspofungin (CS) were obtained
from Axon Lab AG, Baden, Switzerland, posaconazole
(PZ) was obtained from Essex Chemie AG, Luzern,
Switzerland. The strips were stored frozen on –20oC
until they were used in the study. Before AFST, they
were left on room temperature for 30 minutes. The agar
formulation used for the E-test was RPMI 1640,
supplemented with 1.5% agar and 2% glucose and
buffered to pH 7.0 with 0.165 M  morpholine
propanesulfonic acid (MOPS) buffer. The 90-mm-
diameter plates contained RPMI at a depth of 4.0 mm.
The plates were inoculated by dipping a sterile swab into
the cell suspension and streaking it across the surface
of the agar in three directions. The plates were dried at
ambient temperature for 15 minutes before applying the
E-test strips. The plates with the E-test strips were
incubated at 35oC and read at 24 or 48 hours for
Aspergillus spp. (depending on the species growth) and
at 48 or 72 hours for other non-Aspergillus moulds. The
E-test MIC of azoles and caspofungin was considered
as the drug concentration at the point where dense
colonial growth intersected the strip, ignoring sparse
subsurface hyphae at the margins. For amphotericin B,
a complete inhibition of growth was read. Microcolonies
within the ellipse were ignored [13].
Data analysis
E-test MICs read at 48 h were compared to BMD
and SYO MICs read at 48 h. Since the E-test scale has
a continuous gradient of concentrations, the MICs with
the E-test in between twofold dilutions were rounded to
the next higher level for comparison [12-14]. For those
Table 1: In vitro susceptibility of Aspergillus spp. a tested by
SYO, and E-test methods.
-, Not determined; 1) MIC50 (MIC causing inhibition of 50% of isolates) values were calculated
for those species with 3 or more isolates.
strains in which the difference in MICs with the BMD was
more than two-fold dilutions, MICs were repeated by
SYO and E-test.
Results
The susceptibility profile of different Aspergillus
spp. to antifungal agents was determined with E-test;
results were compared with previous results of SYO
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method. For non-Aspergillus moulds SYO and E-test
were performed, and results were compared with
previous results of CLSI BMD method. All strains
produced detectable growth after 48h of incubation,
except one strain of A. glaucus and one strain of
Paecilomyces spp. that required 6 and 7 days of
incubation respectively for growth in SYO plates. The
susceptibility testing was performed twice for these
strains to ensure avoidance of technical errors. Results
with control strain were within the described range
according to reference documents [9]. E-test inhibition
ellipses were clear. Triazole ellipses, especially those of
voriconazole were wider than amphotericin B ellipses for
most isolates. Tables 1 and 2 summarize the antifungal
susceptibility profiles of the 33 strains of Aspergillus spp.
and non-Aspergillus moulds to amphotericin B,
itraconazole, voriconazole, posaconazole and
caspofungin obtained with the E-test, to amphotericin B,
fluconazole, itraconazole, ketoconazole, flucytosine and
voriconazole as determined by the SYO method and to
amphotericin B, itraconazole, voriconazole and
caspofungin as determined with the CLSI BMD.
SYO versus E-test
In 9/33 (27%) mould isolates amphotericin B
MICs were found to be identical by SYO and E-test, in 12/
33 (36%) isolates amphotericin B MICs differed by ±1
dilution, and in 7 isolates (21%) they differed by ±2
dilutions (Table 3). Differences were most frequently
due to higher MICs with the E-test. Discrepancies (greater
than ± 2 dilutions) between the MICs determined by the
SYO method and E-test were demonstrated in 5/33
(15%) isolates tested against amphotericin B: 1 A.
glaucus, 1 Scedosporium prolificans, 2 Scedosporium
apiospermum, and 1 Paecilomyces spp., and these
discrepancies were almost always due to higher MICs
with the E-test (except for A. glaucus, for which E-test
result was lower). Overall, 4 strains were classified as
amphotericin B ‘’resistant” (MIC>32 μg/ml) by the Etest,
but SYO method failed to detect these strains. In 16 out
of 33 (48%) moulds itraconazole MICs were determined
as identical by both methods, in 11/33 (33%) isolates the
itraconazole MICs differed by ± 1 dilution with E-test, and
in 4/33 (12%) the itraconazole MICs were two dilutions
higher by the E-test. Two (6%) major discrepancies
between the itraconazole MICs with both methods were
observed. For voriconazole, in 11/33 (33%) voriconazole
MICs were found to be identical by both methods, in 13/
33 (39%) isolates the voriconazole MICs differed by ±1
dilution. In 4/33 (12%) the voriconazole MICs differed by
two dilutions. In 5 (15%) strains major discrepancies with
more than 2 dilution higher values in favour of E-test
were registered.
SYO versus M-BMD
In 4/17 (24%) non-Aspergillus moulds,
amphotericin B MICs were determined to be identical by
SYO method and BMD, in 3/17 (18%) isolates
amphotericin B MICs differed by one dilution, and in 6/17
(35%) MICs for amphotericin B differed by two dilutions
higher. Where differences by one or two dilutions were
observed, they were due to higher MICs with BMD. In 4
(24%) strains, major discrepancies with more than 2
dilutions higher values occurred and they were due to
higher MICs with BMD. In 4/17 (24%) isolates of non-
Aspergillus moulds, the itraconazole MICs were identical
by both methods, in 3/17 (18%) isolates differed by ±1
dilution, and in 1 (6%) isolate by two dilutions. In 4 (24%)
Table 2: In vitro susceptibility of non-Aspergillus moulds a
tested by SYO, E-test, and BMD methods.
-, Not determined; 1) MIC50 (MIC causing inhibition of 50% of isolates) values were calculated
for those species with 3 or more isolates; 2) MIC50 was not determined because 1 of 3 values
was not determined.
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strains, major discrepancies with more than 2 dilutions
were noticed. In 5/17 (29%) the MIC with BMD was not
determined (data not shown). In 4/17 (24%) isolates of
non-Aspergillus moulds, the voriconazole MICs were
determined identical by both methods, in 10/17 (59%)
isolates they differed by ±1 dilution, and in one (6%)
isolate by two dilutions. In 2 (12%) strains, major
discrepancies with more than 2 dilutions were noticed.
The MIC results obtained by both BMD and E-
test methods demonstrated that voriconazole was very
active against this diverse array (5 different genera) of
opportunistic non-Aspergillus moulds (69.7% susceptible
at MIC <1 μg/ml). Elevated MICs as determined by all
methods were more frequently observed with Fusarium
spp., as well as with isolates of Scopulariopsis spp. and
Paecilomyces spp. When discrepancies between the
BMD and E-test MICs were noted, the E-test tended to
give lower values with voriconazole. All isolates of
Aspergillus spp. were inhibited with <0.5 μg/ml of
voriconazole. These results demonstrate the excellent
efficacy of voriconazole against Aspergillus species and
suggest that voriconazole may be the treatment of
choice in invasive aspergillosis caused by A.fumigatus
and A.flavus. Indeed, this is supported by clinical studies,
which have shown better responses to voriconazole
than to amphotericin B in patients with invasive
aspergillosis (21-24).
Discussion
We found the E-test to be a very simple method
for determination of susceptibility profile of filamentous
moulds to all antifungals, except of few difficulties
experienced with caspofungin, where residual growth
was noticed. RPMI agar with glucose (final concentration,
2%) supported optimal growth of all species tested and
provided good agreement with the MICs obtained with
BMD. Szekely et al. [25] used RPMI agar and 48 h of
incubation and found that the inhibition ellipses were
clear for most isolates. They concluded that the E-test
procedure was reproducible and served as a suitable
method for AFST of moulds. Pfaller et al. demonstrated
that the E-test was able to detect resistance to
itraconazole among filamentous fungi [15]. Additionally,
the depth of the agar can influence the MIC. Therefore,
the manufacturer’s recommendations should be followed
when attempting to obtain MICs by E-test. The SYO
method has the advantage of being technically easy to
perform and able to determine objective and quantitative
MIC endpoints [27]. The BMD method is regarded as the
reference method, however, a main disadvantage of this
procedure is that the preparation of the trays is time
consuming and laborious.
The results of this study show that the overall
agreement at ±2 dilutions between the three methods is
relatively high. However, the correlation of the SYO
method to the BMD method is only moderate for
amphotericin B and itraconazole. The vast majority of
Table 3: Agreement between SYO and E-test, BMD and SYO and
M-BMD and E-test for three agents tested against 33 isolates of
Aspergillus spp. and non- Aspergillus moulds.
E-test versus MBD
In 7/17 (41%) isolates of non-Aspergillus moulds,
amphotericin B MICs were determined to be same by
both methods, in 1 (6%) isolate amphotericin B MIC
differed by ±1, and in 6/17 (35%) amphotericin B MIC
differed by ±2 dilutions. Discrepancies (greater than ±2
dilutions) between the MICs determined by BMD and
Etest were demonstrated in 3/17 (18% tested against
amphotericin B. In 6/17 (35%) isolates of non-Aspergillus
moulds, itraconazole MICs were determined to be
identical by both methods, in 1 (6%) isolate itraconazole
MIC differed by ±1 dilution, and in 3/17 (18%) isolates
they differed by ±2 dilutions. Discrepancies (greater
than ±2 dilutions) between the MICs determined by the
BMD and E-test were demonstrated in 2/17 (12%) tested
against itraconazole. In 5/17 (29%) the MIC with the
BMD was not determined (data not shown). In 4/17
(24%) isolates of non-Aspergillus moulds, voriconazole
MICs were determined to be identical by both methods,
in 7/17 (41%) isolates voriconazole MICs differed by ±1
dilution, and in 3 (18%) isolates voriconazole MIC differed
by ±2 dilutions. Major discrepancies (greater than ±2
dilutions) between the MICs determined by BMD and
Etest were demonstrated in 3/17 (18%) tested against
voriconazole (always due to higher MICs with E-test).
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differing results are due to higher MICs with the BMD
method. In particular, SYO was unable to detect some of
the potentially amphotericin B resistant strains. Likewise,
when comparing the results of the SYO method to the
Etest method for amphotericin B and itraconazole, the
majority of differing results are in favour of higher MICs
with the E-test. Similarly, Meletiadis et al. [14] have
shown lower SYO MICs for itraconazole in several
Aspergillus spp. (except A. ustus). They could not show
this effect for amphotericin B. In contrast, in another
study in which also E-test, SYO and BMD were compared
[27], MIC ranges by E-test were broader and always
higher for amphotericin B and itraconazole.
The MIC results obtained by E-test methods
demonstrated that posaconazole was very active against
all Aspergillus spp. (all susceptible at MIC <0.25 μg/ml),
but showed poor activity against some of the non-
spergillus moulds (Fusarium spp., Scedosporium spp.,
Scopulariopsis spp.) (28, 29). SYO method includes
fluconazole and 5-flucytosine, to which in general
filamentous fungi are resistant and are not useful for
therapy (panel testing thus generates more costs). Also,
with SYO it is not possible to test caspofungin for
moulds, because a majority of the strains appear resistant,
whereas E-test allows testing of antifungal drugs
according to the needs of the clinician (including
caspofungin and posaconazole). However, SYO has
potential value for the performance of susceptibility
testing of filamentous fungi to other antifungal agents,
such as itraconazole and voriconazole, so it could be a
good and reliable alternative for in vitro AFST, especially
with SYO8 which includes the newer triazole,
posaconazole. But the results provided with this study
indicate that SYO is not sensitive enough for in vitro
detection of resistance to amphotericin B in Aspergillus
spp. and non-Aspergillus moulds.
In conclusion, on the basis of data from this
study and other studies as well, the ability of E-test to
generate MIC data for filamentous fungi that are
comparable to those obtained by the CLSI broth
microdilution method has been shown and thus a potential
value for E-test for the use for AFST of mould pathogens
has been proved. This could be attractive to microbiology
laboratories, since it will provide the flexibility to test one
or more commonly used antifungal agents selectively
against a wide variety of moulds that may be encountered
clinically. The higher amphotericin B MICs obtained by
the E-test as compared to SYO for some strains suggests
that this method could be more useful in detection of
mould isolates potentially resistant to amphotericin B. In
general, both the E-test and the SYO methods are
promising, but require further investigation to identify the
optimum conditions for their use in the testing of the
susceptibilities of filamentous fungi to antifungal agents,
including new azoles and the new class of echinocandins.
Optimization of these tests might require
adjustments depending on the species tested. However,
more studies are required to determine which methods
show the best agreement with in vivo results, and thus,
the clinical value of these in vitro results should be
determined in clinical trials.
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